Drug Trial Radar · NCT00722735
Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)
Last checked: Nov 19, 2026Latest source record: Jun 11, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 2008
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.
Conditions
- Urinary Tract Infections
Interventions
FinafloxacinDrug
Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
CiprofloxacinDrug
Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bacteriological eradication of the initial pathogen.Time frame: 4-6 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Medical practice, Dr. J. Hein (Principal Study Investigator)
Marburg, Germany
National University Hospital
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.